<DOC>
	<DOCNO>NCT00033709</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Thalidomide may stop growth cancer stop blood flow tumor . Combining temozolomide thalidomide may kill tumor cell . PURPOSE : Phase II trial study effectiveness combine temozolomide thalidomide treat patient metastatic , locally advanced , unresectable leiomyosarcoma .</brief_summary>
	<brief_title>Temozolomide Thalidomide Treating Patients With Metastatic , Locally Advanced , Unresectable Leiomyosarcoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine efficacy temozolomide thalidomide patient metastatic , locally advanced , unresectable leiomyosarcoma . - Determine time progression patient treat regimen . - Determine overall survival patient treat regimen . - Determine clinical laboratory toxic effect tolerability regimen patient . OUTLINE : Patients receive oral temozolomide daily 7 day every week oral thalidomide daily . Treatment continue 26 week absence disease progression unacceptable toxicity . PROJECTED ACCRUAL : A total 15-25 patient accrue study within 7.5-25 month .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Leiomyosarcoma</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm leiomyosarcoma Metastatic , locally advanced , unresectable Ineligible high priority national institutional study At least 1 unidimensionally measurable lesion document radiologic study At least 2 cm 2 cm Not previously irradiate unless disease progression site evident No brain metastasis PATIENT CHARACTERISTICS : Age : 18 Performance status : SWOG 02 Life expectancy : More 2 month Hematopoietic : WBC great 3,000/mm^3 Neutrophil count least 1,500/mm^3 Platelet count great 70,000/mm^3 Hemoglobin least 10 g/dL Hepatic : Bilirubin le upper limit normal ( ULN ) SGOT SGPT less 1.5 time ULN* Alkaline phosphatase less 2 time ULN* NOTE : * Less 5 time ULN document liver disease Renal : Creatinine le 1.5 time normal OR Creatinine clearance great 60 mL/min BUN le 1.5 time normal Other : Not pregnant nursing Negative pregnancy test Fertile patient must use 2 form effective contraception 4 week , , 4 week study therapy No acute infection require systemic antibiotic No frequent vomit medical condition would preclude intake oral medication ( e.g. , partial bowel obstruction ) No serious medical psychiatric illness would preclude study participation No prior malignancy except curatively treat carcinoma situ cervix skin cancer PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : At least 4 week since prior chemotherapy No 3 prior systemic chemotherapy regimens metastatic , locally advanced , unresectable leiomyosarcoma Prior dacarbazine allow Endocrine therapy : Not specify Radiotherapy : See Disease Characteristics At least 4 week since prior radiotherapy No prior radiotherapy 50 % bone marrow Concurrent radiotherapy local control palliative therapy painful bony soft tissue lesion allow Surgery : At least 4 week since prior surgery recover Other : Recovered prior therapy No concurrent investigational drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2005</verification_date>
	<keyword>adult leiomyosarcoma</keyword>
	<keyword>stage III adult soft tissue sarcoma</keyword>
	<keyword>recurrent adult soft tissue sarcoma</keyword>
	<keyword>stage III uterine sarcoma</keyword>
	<keyword>stage IV uterine sarcoma</keyword>
	<keyword>recurrent uterine sarcoma</keyword>
	<keyword>uterine leiomyosarcoma</keyword>
	<keyword>stage IV adult soft tissue sarcoma</keyword>
</DOC>